X0206 3 2013-08-21 0 0001311596 Regado Biosciences Inc RGDO 0001189158 NEFF P SHERRILL C/O QUAKER BIOVENTURES CIRA CENTRE, 2929 ARCH STREET PHILADELPHIA PA 19104 1 0 1 0 Common Stock, par value $0.001 per share 35928 I See footnote Series B Preferred Stock 2005-07-27 Common Stock, par value $0.001 per share 399201 I See footnote Series C Preferred Stock 2007-03-15 Common Stock, par value $0.001 per share 273468 I See footnote Series D Preferred Stock 2009-12-17 Common Stock, par value $0.001 per share 360529 I See footnote Series D Preferred Stock 2011-05-25 Common Stock, par value $0.001 per share 104723 I See footnote Series E Preferred Stock 2012-12-18 Common Stock, par value $0.001 per share 43171 I See footnote Series E Preferred Stock 2013-03-22 Common Stock, par value $0.001 per share 5191 I See footnote Stock Option (right to buy) 4.51 2020-04-30 Common Stock, par value $0.001 per share 8788 D Stock Option (right to buy) 11.69 2018-12-08 Common Stock, par value $0.001 per share 2095 D Stock Option (right to buy) 12.53 2018-02-13 Common Stock, par value $0.001 per share 2095 D Stock Option (right to buy) 10.86 2017-02-21 Common Stock, par value $0.001 per share 2095 D Stock Option (right to buy) 3.34 2015-12-20 Common Stock, par value $0.001 per share 2095 D The Reporting Person is a partner in Quaker Partners Management, L.P., which manages the investments of Quaker BioVentures L.P. ("Quaker BioVentures"). Quaker Partners Management, L.P. has a pecuniary interest in securities of the Issuer owned by Quaker BioVentures. The Reporting Person disclaims beneficial ownership of the securities held by Quaker BioVentures, except to the extent of his pecuniary interest therein. The shares of Series B Preferred Stock have no expiration date and shall automatically convert upon the consummation of the Issuer's initial public offering at a conversion ratio of 1 share of Series B Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The shares of Series C Preferred Stock have no expiration date and shall automatically convert upon the consummation of the Issuer's initial public offering at a conversion ratio of 1 share of Series C Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The shares of Series D Preferred Stock have no expiration date and shall automatically convert upon the consummation of the Issuer's initial public offering at a conversion ratio of 1 share of Series D Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The shares of Series E Preferred Stock have no expiration date and shall automatically convert upon the consummation of the Issuer's initial public offering at a conversion ratio of 1 share of Series E Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. This option is fully vested and exercisable. /s/ P. Sherrill Neff 2013-08-21